Sanjay Kaul, M.B.B.S., FACC

General Statement of Disclosure:

CONSULTING FEES/HONORARIA: Boehringer-Ingelhiem(SIGNIFICANT), FDA Cardiorenal and Endocrine and Metabolic Advisory Panels(MODEST), Sanofi-Aventis(SIGNIFICANT), Novo Nordisk Inc.(SIGNIFICANT), Abbott Laboratories(SIGNIFICANT), Respicardia(SIGNIFICANT) OTHER FINANCIAL BENEFIT: JNJ(SIGNIFICANT)

View Full Disclosure